NARATRIPTAN
Clinical safety rating: avoid
Contraindicated (not allowed)
Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.
| Metabolism | Hepatic via cytochrome P450 (CYP) enzymes, primarily CYP3A4, with minor contribution from other isoforms. Metabolites are inactive. |
| Excretion | Renal: ~50% (metabolites and unchanged drug); Fecal: ~30%; Biliary: minor; unchanged naratriptan accounts for <10% of urinary recovery. |
| Half-life | Terminal elimination half-life is approximately 5–6 hours (range 4–8 hours), supporting a twice-daily dosing interval for acute migraine treatment and allowing once-daily dosing for menstrual migraine prophylaxis. |
| Protein binding | ~29% bound, primarily to albumin. |
| Volume of Distribution | Approximately 2.4 L/kg (range 1.8–3.0 L/kg), consistent with extensive tissue distribution beyond plasma. |
| Bioavailability | Oral: 74% (range 63–95%); subcutaneous: ~100% (but not marketed). |
| Onset of Action | Oral: 1–3 hours; subcutaneous: 10–20 minutes (not clinically available). |
| Duration of Action | Clinical effect lasts 24 hours for headache relief, with a lower rate of headache recurrence at 24 hours compared to sumatriptan (17–28% vs. 22–35%). |
2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment recommended; however, use with caution in severe renal impairment (CrCl <15 mL/min) due to limited data. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), maximum dose is 2.5 mg per day; do not exceed single dose of 2.5 mg. |
| Pediatric use | Safety and efficacy not established in patients under 18 years; no approved pediatric dosing guidelines. |
| Geriatric use | Use with caution due to potential for reduced hepatic and renal function; no specific dose adjustment recommended, but start at low end of dosing range (2.5 mg). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other 5-HT1 agonists can have additive effects Contraindicated in ischemic heart disease and uncontrolled hypertension.
| Breastfeeding | Unknown if excreted in human milk; M/P ratio not established. Due to low molecular weight (335.46 g/mol), excretion is possible. Caution advised; monitor infant for adverse effects (e.g., drowsiness, diarrhea). |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester unless benefit outweighs risk. Second/third trimester: limited data; use only if clearly needed. |
■ FDA Black Box Warning
Naratriptan is contraindicated in patients with ischemic heart disease or coronary artery vasospasm due to risk of myocardial ischemia/infarction and cerebrovascular events.
| Common Effects | Dizziness |
| Serious Effects |
["Ischemic heart disease (angina, history of MI, silent ischemia)","Coronary artery vasospasm (Prinzmetal's angina)","History of stroke or transient ischemic attack","Uncontrolled hypertension","Hemiplegic or basilar migraine","Severe hepatic impairment (Child-Pugh C)","Severe renal impairment (CrCl <15 mL/min)","Concurrent use of ergotamine derivatives or other 5-HT1 agonists within 24 hours","Hypersensitivity to naratriptan or any component"]
| Precautions | ["Cardiac events: risk of myocardial ischemia, infarction, and arrhythmias","Cerebrovascular events: stroke, subarachnoid hemorrhage","Serotonin syndrome: especially with concomitant serotonergic drugs","Medication overuse headache: chronic use can lead to daily headaches","Severe hepatic impairment: reduce dose or avoid","Severe renal impairment: contraindicated"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure and heart rate during use in pregnancy. For prolonged use, fetal growth assessment via ultrasound recommended. In lactation, monitor infant for sedation, poor feeding. |
| Fertility Effects | Limited data. Animal studies show no impairment of fertility at sub-toxic doses. In humans, no specific reports of impaired fertility; however, triptans may potentially affect ovarian function indirectly via vascular effects, though unlikely. |